Alkermes to Present at the 43rd Annual J.P. Morgan Healthcare Conference

02.01.25 22:00 Uhr

Werte in diesem Artikel
Aktien

27,60 EUR 0,20 EUR 0,73%

DUBLIN, Jan. 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Wednesday, Jan. 15, 2025 at 11:15 a.m. PST (2:15 p.m. EST/7:15 p.m. GMT), followed by a question and answer session. The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402

Alkermes plc Logo (PRNewsfoto/Alkermes plc)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302341496.html

SOURCE Alkermes plc

Ausgewählte Hebelprodukte auf Alkermes

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Alkermes

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Alkermes PLC

Wer­bung

Analysen zu Alkermes PLC

DatumRatingAnalyst
31.05.2019Alkermes NeutralH.C. Wainwright & Co.
14.12.2018Alkermes UnderperformWolfe Research
07.08.2018Alkermes HoldStifel, Nicolaus & Co., Inc.
06.06.2018Alkermes BuyB. Riley FBR, Inc.
16.10.2017Alkermes Equal WeightBarclays Capital
DatumRatingAnalyst
07.08.2018Alkermes HoldStifel, Nicolaus & Co., Inc.
06.06.2018Alkermes BuyB. Riley FBR, Inc.
07.10.2015Alkermes OverweightBarclays Capital
21.05.2015Alkermes OverweightBarclays Capital
08.01.2015Alkermes BuyMizuho
DatumRatingAnalyst
31.05.2019Alkermes NeutralH.C. Wainwright & Co.
16.10.2017Alkermes Equal WeightBarclays Capital
DatumRatingAnalyst
14.12.2018Alkermes UnderperformWolfe Research

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Alkermes PLC nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"